{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:49:26Z","timestamp":1788306566310,"version":"build-2803163510"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The measurement of Fibroblast growth factor 23 (FGF23) may be useful in the diagnosis and management of abnormal phosphate metabolism in both patients with preserved renal function or with chronic kidney disease (CKD). FGF-23 tests differ considerably by molecule assayed (iFGF23 or cFGF23), analytical performance and reference ranges. We establish iFGF23 Upper Reference Limits (URL) in apparently healthy pediatric individuals using automated immunochemiluminescent assay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We measured the levels of plasma iFGF23 from 115 samples from apparently healthy pediatric subjects [59 (51.3%) individuals were male; median age 10 years (range 1\u201318)] included in an observational study conducted at Policlinico University Hospital of Bari. The method used for the iFGF23 assay was immunochemiluminescent sandwich assay developed by DiaSorin on the Liaison XL platform. Statistical calculation of 95% reference interval, right-sided (CLSI C28-A3) and verification of age and sex covariables was performed for the calculation of the URL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The URL concentration of iFGF23 was 61.21 pg\/mL (58.63 to 63.71, 90% CI). No significant differences were found between the median concentrations of iFGF23 differentiated by sex and age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The dosage of iFGF23 is important both for the differential diagnosis of the various forms of rickets, and for the subsequent monitoring of the effectiveness of drug treatment. We have established the URL for the iFGF23 Liaison test in apparently healthy pediatric subjects. The availability of iFGF23 pediatric reference values will allow a better clinical use of the test.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2022.1018523","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:18:15Z","timestamp":1667953095000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Determination of iFGF23 Upper Reference Limits (URL) in healthy pediatric population, for its better correct use"],"prefix":"10.3389","volume":"13","author":[{"given":"Vincenzo","family":"Brescia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonietta","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Lovero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Capobianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella Vita","family":"Marsico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"De Chirico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Varraso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Pia","family":"Cazzolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Di Serio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-018-0087-2","article-title":"Renal and extrarenal effects of fibroblast growth factor 23","volume":"15","author":"Vervloet","year":"2019","journal-title":"Nat Rev Nephrol Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0902006107","article-title":"Isolated c-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation","volume":"107","author":"Goetz","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nature05315","article-title":"Klotho converts canonical FGF receptor into a specific receptor for FGF23","volume":"444","author":"Urakawa","year":"2006","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nrneph.2016.164","article-title":"The role of phosphate in kidneydisease","volume":"13","author":"Vervloet","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.0301264","article-title":"FGF-23 is a potent regulator of vitamin d metabolism and phosphate homeostasis","volume":"19","author":"Shimada","year":"2004","journal-title":"J Bone Miner Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa665","article-title":"Intact and c-terminal FGF23 assays\u2013do kidney function, inflammation, and low iron influence relationships with outcomes","volume":"105","author":"Sharma","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00328.x","article-title":"Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers","volume":"64","author":"Larsson","year":"2003","journal-title":"Kidney Int"},{"key":"B8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.17458\/per.vol17.2019.gi.fgf23anddisordersphosphate","article-title":"Imel FGF23 and associated disorders of phosphate wasting","volume":"17","author":"Gohil","year":"2019","journal-title":"Pediatr Endocrinol Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8821292","article-title":"FGF23: A review of its role in mineral metabolism and renal and cardiovascular disease","volume":"2021","author":"Kurpas","year":"2021","journal-title":"Dis Markers"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1424","article-title":"Klotho, fibroblast growth factor-23, and the renin-angiotensin system \u2013 an analysis from the PEACE trial","volume":"21","author":"Bergmark","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-019-0152-5","article-title":"Clinical practice recommendations for the diagnosis and managementof X-linked hypophosphataemia","volume":"15","author":"Haffner","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1530\/EC-20-0291","article-title":"Clinical guidelines for burosumab in the treatment of XLH inchildren and adolescents: British paediatric and adolescent bone group recommendations","volume":"9","author":"Padidela","year":"2020","journal-title":"Endocr Connect"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2013-0208","article-title":"Method-specific differences in plasma fibroblast growth factor 23 measurement using four commercial ELISAs","volume":"51","author":"Smith","year":"2013","journal-title":"Clin Chem Lab Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-013-0451-x","article-title":"FGF23 concentrations measured using \u201cIntact\u201d assays similar but not interchangeable","volume":"45","author":"Sinha","year":"2013","journal-title":"Int Urol Nephrol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-011-0306-4","article-title":"Evaluation of a new automated chemiluminescence immunoassay for FGF23","volume":"30","author":"Shimizu","year":"2012","journal-title":"J Bone Miner Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1177\/0004563219826161","article-title":"Biological variation of intact fibroblast growth factor 23 measured on a fully automated chemiluminescent platform","volume":"56","author":"Jabor","year":"2019","journal-title":"Ann Clin Biochem"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1373\/jalm.2016.022467","article-title":"Stability of fibroblast growth factor 23 in human plasma","volume":"1","author":"Cui","year":"2017","journal-title":"J Appl Lab Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/00365513.2018.1526411","article-title":"Technical and diagnostic performance of a new fully automated immunoassay for the determination of intact fibroblast growth factor 23 (FGF23)","volume":"78","author":"van Helden","year":"2018","journal-title":"Scand J Clin Lab Invest"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-017-0307-y","article-title":"Evaluation of a new fully automated assay for plasma intact FGF23","volume":"101","author":"Souberbielle","year":"2017","journal-title":"Calcif Tissue Int"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1515\/med-2021-0288","article-title":"Serum intact fibroblast growth factor 23 in healthy paediatric population","volume":"16","author":"Stanczyk","year":"2021","journal-title":"Open Med"},{"key":"B21","volume-title":"User verification of performance for precision and trueness; approved guideline","year":"2005"},{"key":"B22","volume-title":"Defining, establishing, and verifying reference intervals in the clinical laboratory; approved guideline","year":"2008"},{"key":"B23","volume-title":"Exploratory data analysis","author":"Tukey","year":"1977"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/children9060896","article-title":"Parathyroid hormone-related peptide (PTHrP): Evaluation of pediatric, covariate-stratified reference intervals","volume":"9","author":"Brescia","year":"2022","journal-title":"Children (Basel)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020881","article-title":"Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia","volume":"348","author":"Jonsson","year":"2003","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021105","article-title":"Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets\/osteomalacia","volume":"87","author":"Yamazaki","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1258\/acb.2009.009066","article-title":"Determination of fibroblast growth factor 23","volume":"46","author":"Heijboer","year":"2009","journal-title":"Ann Clin Biochem"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2019.02.032","article-title":"Pre-analytical stability of FGF23 with the contemporary immunoassays","volume":"493","author":"Dirks","year":"2019","journal-title":"Clin Chim Acta"},{"key":"B29","article-title":"Evaluation of human fibroblast growth factor 23 (FGF-23) cterminal and intact enzyme-linked immunosorbent-assays in end-stage renal disease patients","volume":"55","author":"Fassbender","year":"2009","journal-title":"Clin Lab"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1177\/0004563213510708","article-title":"Fibroblast growth factor 23","volume":"51","author":"Smith","year":"2014","journal-title":"Ann Clin Biochem"},{"key":"B31","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1186\/s12882-018-1127-7","article-title":"The stability and variability of serum and plasma fibroblast growth factor-23 levels in a haemodialysis cohort","volume":"19","author":"Damasiewicz","year":"2018","journal-title":"BMC Nephrol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-016-3543-5","article-title":"Stability and degradation of fibroblast growth factor 23 (FGF23): the effect of time and temperature and assay type","volume":"27","author":"El-Maouche","year":"2016","journal-title":"Osteopor Int"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1811","article-title":"Biological variability of plasma intact and c-terminal FGF23 measurements","volume":"97","author":"Smith","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-022-02238-5","article-title":"Factors associated with 1\u2212year changes in serum fibroblast growth factor 23 levels in pediatric patients with chronic kidney disease","volume":"9","author":"Miyazaki","year":"2022","journal-title":"Clin Exp Nephrol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-3709","article-title":"Cord blood ferritin and fibroblast growth factor-23 levels in neonates","volume":"101","author":"Ali","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1159\/000443988","article-title":"Fibroblast growth factor 23 concentrations reflect sex differences in mineral metabolism and growth in early infancy","volume":"85","author":"Holmlund-Suila","year":"2016","journal-title":"Hormone Res paediatr"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01211","article-title":"Sex and iron modify fibroblast growth factor 23 concentration in 1-Year-Old children","volume":"102","author":"Holmlund-Suila","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1258\/acb.2012.011274","article-title":"Paediatric reference values for the c-terminal fragment of fibroblast-growth factor-23, sclerostin, bone-specific alkaline phosphatase and isoform 5b of tartrate-resistant acid phosphatase","volume":"49","author":"Fischer","year":"2012","journal-title":"Ann Clin Biochem"},{"key":"B39","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.bone.2014.05.012","article-title":"Fibroblast growth factor 23 and klotho serum levels in healthy children","volume":"66","author":"Gkentzi","year":"2014","journal-title":"Bone"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.070107","article-title":"FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets","volume":"22","author":"Imel","year":"2007","journal-title":"J Bone mineral Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfp699","article-title":"Fibroblast growth factor-23 and early decrements in kidney function: the heart and soul study","volume":"25","author":"Ix","year":"2010","journal-title":"Nephrol Dial Transpl"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-4038","article-title":"FGF23 is not associated with age-related changes in phosphate, but enhances renal calcium reabsorption in girls","volume":"102","author":"Mitchell","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0704446104","article-title":"Evidence for a signaling axis by which intestinal phosphate rapidly modulates renal phosphate reabsorption","volume":"104","author":"Berndt","year":"2007","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00279.2009","article-title":"Regulation of rat intestinal Na-dependent phosphate transporters by dietary phosphate","volume":"297","author":"Giral","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00467-009-1273-z","article-title":"Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): Implications for disorders of phosphate metabolism","volume":"25","author":"Gattineni","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-021119-034650","article-title":"Regulation and effects of FGF23 in chronic kidney disease","volume":"82","author":"Musgrove","year":"2020","journal-title":"Annu Rev Physiol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfs109","article-title":"Investigating FGF-23 concentrations and its relationship with declining renal function in paediatric patients with pre-dialysis CKD stages 3\u20135","volume":"27","author":"Sinha","year":"2012","journal-title":"Nephrol Dial Transpl"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05840513","article-title":"Disordered FGF23 and mineral metabolism in children with CKD","volume":"9","author":"Portale","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00022.2017","article-title":"Phosphate as a signaling molecule and its sensing mechanism","volume":"98","author":"Michigami","year":"2018","journal-title":"Physiol Rev"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1097\/01.mnh.0000447020.74593.6f","article-title":"Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease","volume":"23","author":"Wolf","year":"2014","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12765","article-title":"Intact FGF23 and \u03b1- klotho during acute inflammation\/sepsis in CKD patients","volume":"46","author":"Dounousi","year":"2016","journal-title":"Eur J Clin Invest"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.55.5507","article-title":"Serum fibroblast growth factor 23 (FGF23) in patients with rheumatoid arthritis","volume":"55","author":"Sato","year":"2016","journal-title":"Internal Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-12-44","article-title":"Fibroblast growth factor 23 contributes to diminished bone mineral density in childhood inflammatory bowel disease","volume":"12","author":"el-Hodhod","year":"2012","journal-title":"BMC Gastroenterol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.641543","article-title":"Consensus recommendations for the diagnosis and management of X-linked hypophosphatemia in Belgium","volume":"19","author":"Laurent","year":"2021","journal-title":"Front Endocrinol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2020-0460","article-title":"FGF23 measurement in burosumab-treated patients: An emerging treatment may induce a new analytical interference","volume":"58","author":"Piketty","year":"2020","journal-title":"Clin Chem Lab Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1018523\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:18:20Z","timestamp":1667953100000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1018523\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,9]]},"references-count":55,"alternative-id":["10.3389\/fendo.2022.1018523"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.1018523","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,9]]},"article-number":"1018523"}}